Suppr超能文献

嵌合NKG2D T细胞需要T细胞和宿主来源的细胞因子分泌以及穿孔素表达,以增加肿瘤抗原呈递和全身免疫。

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

作者信息

Barber Amorette, Sentman Charles L

机构信息

Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756, USA.

出版信息

J Immunol. 2009 Aug 15;183(4):2365-72. doi: 10.4049/jimmunol.0900721. Epub 2009 Jul 22.

Abstract

Treatment of mice bearing established ovarian tumors with T cells expressing chimeric NKG2D receptors (chNKG2D) develop protective host immune responses to tumor Ags. In this study, the mechanisms that chNKG2D T cells require to induce host immunity against ovarian tumors and which of the host immune cells are involved in tumor elimination were determined. Treatment with chNKG2D T cells led to a sustained, increased IFN-gamma production by host NK, CD4(+), and CD8(+) T cells in the spleen and at the tumor site and this continued for many weeks after T cell injection. Tumor Ag presentation was enhanced in chNKG2D T cell-treated mice, and there were greater numbers of tumor-specific T cells at the tumor site and in draining lymph nodes after treatment with chNKG2D T cells. The increase in host cell cytokine secretion and Ag presentation was dependent on chNKG2D T cell-derived perforin, IFN-gamma, and GM-CSF. Host immune mechanisms were involved in tumor elimination because inhibition of tumor growth was limited in mice that lacked perforin, IFN-gamma, NK cells, or T and B cells (Rag1(-/-)). There was no role for host-derived GM-CSF or CD1-dependent NKT cells, because mice deficient in these were able to clear tumors as well as treated wild-type B6 mice. In summary, chNKG2D T cells required both cytotoxicity and cytokine secretion as well as the participation of host immune cells for development of a host antitumor immune response and complete efficacy.

摘要

用表达嵌合NKG2D受体(chNKG2D)的T细胞治疗已建立卵巢肿瘤的小鼠,可产生针对肿瘤抗原的保护性宿主免疫反应。在本研究中,确定了chNKG2D T细胞诱导宿主抗卵巢肿瘤免疫所需的机制以及参与肿瘤清除的宿主免疫细胞。用chNKG2D T细胞治疗导致宿主脾脏和肿瘤部位的NK、CD4(+)和CD8(+) T细胞持续增加干扰素-γ的产生,并且在T细胞注射后的许多周内持续存在。chNKG2D T细胞治疗的小鼠中肿瘤抗原呈递增强,用chNKG2D T细胞治疗后肿瘤部位和引流淋巴结中有更多的肿瘤特异性T细胞。宿主细胞细胞因子分泌和抗原呈递的增加依赖于chNKG2D T细胞来源的穿孔素、干扰素-γ和粒细胞-巨噬细胞集落刺激因子。宿主免疫机制参与了肿瘤清除,因为在缺乏穿孔素、干扰素-γ、NK细胞或T和B细胞(Rag1(-/-))的小鼠中肿瘤生长抑制受到限制。宿主来源的粒细胞-巨噬细胞集落刺激因子或CD1依赖性NKT细胞没有作用,因为缺乏这些的小鼠能够像治疗的野生型B6小鼠一样清除肿瘤。总之,chNKG2D T细胞需要细胞毒性和细胞因子分泌以及宿主免疫细胞的参与才能产生宿主抗肿瘤免疫反应并实现完全疗效。

相似文献

2
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
J Immunol. 2009 Dec 1;183(11):6939-47. doi: 10.4049/jimmunol.0902000. Epub 2009 Nov 13.
6
Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
J Immunol. 2001 Dec 1;167(11):6497-502. doi: 10.4049/jimmunol.167.11.6497.
7
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Cancer Res. 2007 May 15;67(10):5003-8. doi: 10.1158/0008-5472.CAN-06-4047.
8
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Immunol Cell Biol. 2013 Jul;91(6):435-40. doi: 10.1038/icb.2013.17. Epub 2013 Apr 30.
9
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
J Immunol. 2013 Mar 1;190(5):2455-63. doi: 10.4049/jimmunol.1201314. Epub 2013 Jan 25.

引用本文的文献

2
Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
Clin Exp Immunol. 2020 Oct;202(1):11-27. doi: 10.1111/cei.13478. Epub 2020 Jul 25.
3
Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.
Mol Ther Oncolytics. 2020 May 4;17:421-430. doi: 10.1016/j.omto.2020.04.013. eCollection 2020 Jun 26.
5
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Mol Ther. 2019 Jun 5;27(6):1114-1125. doi: 10.1016/j.ymthe.2019.03.011. Epub 2019 Mar 20.
6
Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.
Best Pract Res Clin Haematol. 2018 Jun;31(2):176-183. doi: 10.1016/j.beha.2018.03.003. Epub 2018 Mar 27.
7
Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Int J Mol Sci. 2018 Jan 7;19(1):177. doi: 10.3390/ijms19010177.
9
Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Immunology. 2017 Nov;152(3):472-483. doi: 10.1111/imm.12784. Epub 2017 Jul 27.
10
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
J Immunol. 2016 Dec 15;197(12):4674-4685. doi: 10.4049/jimmunol.1600769. Epub 2016 Nov 14.

本文引用的文献

1
Tumor cell recognition by the NK cell activating receptor NKG2D.
Eur J Immunol. 2008 Nov;38(11):2957-61. doi: 10.1002/eji.200838833.
2
NKG2D ligands in tumor immunity.
Oncogene. 2008 Oct 6;27(45):5944-58. doi: 10.1038/onc.2008.272.
3
4
Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.
Best Pract Res Clin Haematol. 2008 Sep;21(3):579-96. doi: 10.1016/j.beha.2008.06.003.
5
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.
Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3.
6
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nat Rev Cancer. 2008 Apr;8(4):299-308. doi: 10.1038/nrc2355.
7
Tumour immunity: effector response to tumour and role of the microenvironment.
Lancet. 2008 Mar 1;371(9614):771-83. doi: 10.1016/S0140-6736(08)60241-X. Epub 2008 Feb 13.
9
Dendritic cells and cytokines in immune rejection of cancer.
Cytokine Growth Factor Rev. 2008 Feb;19(1):93-107. doi: 10.1016/j.cytogfr.2007.10.003. Epub 2007 Dec 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验